GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU
Approval Conditional On Further Studies, Risk Management Plan
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.
You may also be interested in...
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.